US tariffs on generic medicines may drastically affect India's pharmaceutical exports, particularly in higher-value formulations, warns GTRI.

US to impose steep tariffs on generic medicine imports from Aug 2028

Indian pharma stocks are likely to remain in focus after US President Donald Trump announced a phased tariff plan for generic medicines, offering a two-year tariff exemption…

US President Trump announced a two-year tariff exemption for imported generic medicines, warning of steep 200% duties if production doesn't shift to the US afterward.

Indian drugmakers export around $9-10 billion worth of generic medicines to the American market every year. | India News

Pharmaceutical stocks came under pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan for imported generic medicines, raising concerns over the…

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After…

The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one hundred percent, eventually reaching…

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…

Donald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analysts believe the long-term impact could be…

In a blow to India’s pharmaceutical industry, the Donald Trump administration has announced up to 200% tariffs on generic drugs that will be applicable in the coming years.

US tariffs on generic medicines may drastically affect India's pharmaceutical exports, particularly in higher-value formulations, warns GTRI.

100% levy from 2028 could accelerate push into higher value medicines

Analysts say that China’s pivot from generics to innovative drugs means the industry is less exposed to US levies.

Trump's generic drug tariff plan raises questions over prices, U.S. manufacturing and which drugmakers stand to gain or lose as details remain unclear.

The Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair pricing and supply chain stability.…

"For our generics coverage, we view the group as relatively well-positioned given: AMRX (significant US infrastructure), TEVA..."

NEW DELHI: India's $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face…

The US is putting generic medicines on the tariff map, with duties set to rise to as much as 200% in the coming years to boost local manufacturing. But will the cure soothe the…